Short Interest in Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Drops By 84.4%

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) was the target of a large decrease in short interest in March. As of March 13th, there was short interest totaling 198,425 shares, a decrease of 84.4% from the February 26th total of 1,274,209 shares. Currently, 1.4% of the company’s stock are sold short. Based on an average daily volume of 233,058 shares, the days-to-cover ratio is currently 0.9 days. Based on an average daily volume of 233,058 shares, the days-to-cover ratio is currently 0.9 days. Currently, 1.4% of the company’s stock are sold short.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. XTX Topco Ltd acquired a new stake in shares of Kairos Pharma during the 2nd quarter valued at approximately $44,000. Two Sigma Investments LP bought a new position in Kairos Pharma during the third quarter worth $54,000. Finally, FNY Investment Advisers LLC acquired a new position in Kairos Pharma in the third quarter worth $27,000.

Kairos Pharma Price Performance

NYSEAMERICAN:KAPA traded up $0.01 during mid-day trading on Tuesday, reaching $0.63. The stock had a trading volume of 87,180 shares, compared to its average volume of 574,912. The company has a market capitalization of $13.10 million, a price-to-earnings ratio of -2.03 and a beta of 2.28. Kairos Pharma has a 1-year low of $0.40 and a 1-year high of $2.11. The stock’s 50 day simple moving average is $0.66 and its two-hundred day simple moving average is $0.90.

About Kairos Pharma

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.